IAP5 Rec'd PCT/PTO 27 JAN 2006

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** Form PTO/SB/08a	Complete if Known	
	Application Number	New Application 10/566292
	Filing Date	January 27, 2006
	First Named Inventor	ALMIRANTE, et al.
	Art Unit	Unknown
	Examiner Name	Unknown
Sheet	1	of	2	Attorney Docket Number	026220-00073

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document	Country Code[3]	Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		97/16405	WO		5/9/1997	Piero DEL SOLDATO, et al.		
		98/21193	WO		5/22/1998	Piero DEL SOLDATO, et al.		
		98/09948	WO		3/12/1998	Piero DEL SOLDATO, et al.		
		2005/023182	WO	A2	3/17/2005	David GARVEY, et al.		
		0 955 294	EP	A2 & A3	11/10/1999	Joseph FINKELSTEIN, et al.		
		00/61537	WO		10/19/2000	Piero DEL SOLDATO		
		1 312 379	EP	A1	5/21/2003	Yoshmi IMURA, et al.		
		03/013499	WO	A2	2/20/2003	Piero DEL SOLDATO		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code. [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/

IAP5 Rec'd PCT/PTO ᵔ 7 JAN 2006

10566292 - GAU: 1626

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO/SB/08b			Application Number	New Application 10/566292
			Filing Date	January 27, 2006
			First Named Inventor	ALMIRANTE, et al.
			Art Unit	UNKNOWN
			Examiner Name	UNKNOWN
Sheet	2	of 2	Attorney Docket Number	026220-00073

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		BRESCHI, et al.; "NO-Sartans: A new Class of Pharmacodynamic Hybrids as Cardiovascular Drugs"; April 30, 2004; Journal of Medicinal Chemistry	
		Sean C. SWEETMAN; "Martindale-The Complete Drug Reference"; Thirty-third Edition	
		Paolo GRESELE; "Role of Proaggregatory and Antiaggregatory Prostaglandins in Hemostasis"; November 1987; The American Society for Clinical Investigation, Inc.; Volume 80, Pages 1435-1445	
		WANSTALL, et al.; "Vascular Smooth Muscle Relaxation Mediated by Nitric Oxide Donors: A Comparison with Acetylcholine, Nitric Oxide and Nitroxyl Ion"; 2001; British Journal of Pharmacology; Pages 463-472	
		HEDNER, et al.; "A Comparison of the Angiotensin II Antagonists Valsartan and Losartan in the Treatment of Essential Hypertension"; 1999; American Journal of Hypertension, Ltd.; Vol. 12 No. 4 Part 3; Pgs. 414-417	
		M.McINTYRE, et al.; "Losartan, An Orally Active Angiotensin (AT1) Receptor Antagonist A Review of Its Efficacy and Safety in Essential Hypertension"; 1997; Vol. 74, No. 2, Pages 181-194	
		Thomas HEDNER; "The Clinical Profile of the Angiotensin II Receptor Blocker Eprosartan"; 2002; Journal of Hypertension Volume 20	
		GRESELE, et al.; "Olmesartan Medoxomil CS-866 Benevas"; 2000; Prous Science; Pages 1217-1218	
		MERLOS, et al.; TELMISARTAN; 1997; Drugs of the Future; Pages 1112-1116	

Examiner Signature	/Joseph Kosack/	Date Considered	11/10/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/